Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Past 24 hours
Any time
Past hour
Past 7 days
Past 30 days
Most recent
Best match
Pharmabiz
11h
Bristol Myers Squibb, 2seventy bio to discontinue enrollment in phase 3 KarMMa-9 study of Abecma in patients with newly diagnosed MM
Bristol Myers Squibb, 2seventy bio to discontinue enrollment in phase 3 KarMMa-9 study of Abecma in patients with newly diagnosed MM: Princeton, New Jersey Friday, September 27, 2 ...
12h
Cobenfy Approval Brings 20% Upside To Bristol Myers Squibb Stock
This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
'Harry Potter' star dies
Helene: How to help
Stadiums to serve as shelters
Promotes watch collection
Targeted Black residents?
Pleads not guilty
World's oldest cheese found
Killer gets life sentence
50/50 ball ownership suit
Producing doc on Diddy
Farmers want flu vaccine
US charges three Iranians
Urgent safety alert for 737s
Fake Biden robocalls fine
Boxes to distribute Narcan
Chinese submarine sank
NC board removes 747K
On Secret Service failures
Ending password-sharing
More executives leave
WI duplicate ballot flap
NIH finds misconduct
Heads to US-Mexico border
ISR targets Hezbollah HQ
Fed inflation gauge cools
Related topics
Bristol-Myers Squibb
2seventy
KarMMa-9
Feedback